Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a volatile investment in recent years, but with a possible game-changing treatment in its portfolio, there may be a ton of upside for Sarepta in the long run.
At the same time, however, the company continues to burn through excessive amounts of cash. Should investors take a chance on this growing biotech business, or is there too much risk here?
The gene therapy market is growing significantly. This year, it's worth a fairly modest $8.7 billion. But it's also fast-growing, with analysts from Grand View Research projecting it to expand at a compounded annual growth rate of 19.2%; by the end of the decade, it should be worth nearly $30 billion. This highlights some great growth opportunities for Sarepta.
Source Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 8.02% for Sarepta Therapeutics compared to the current price of 120.35 €.
